HDACi treatment has been reported to activate caspase-9, caspase-3, and caspase-8 and inhibit anti-apoptotic Bcl-2 family members (Bcl-2 and Bcl-XL) in breast, colon, hematopoietic, lung, melanoma, ovarian, prostatic, renal, and stomach cancer cell lines using a novel hydroxamate-based HDACI, CG0006 (Hwang et al. 2009). The gene discussed is BCL2; the disease is gastric cancer.